There is limited information available on the specific topic of an increase in liver enzymes during long-term Tigecycline therapy. However, according to the prescribing information for Tigecycline, increases in liver enzymes have been reported in clinical trials. The frequency of this occurrence is not explicitly stated in the prescribing information.

A study published in the Journal of Antimicrobial Chemotherapy in 2014, which can be found on the National Center for Biotechnology Information (NCBI) website, analyzed the safety and efficacy of Tigecycline in the treatment of various infections. The study included 1,516 patients, of whom 763 received Tigecycline. The study found that elevations in liver enzymes occurred in 13.3% of patients treated with Tigecycline, compared to 6.5% of patients in the comparator group. However, this study did not specifically focus on long-term therapy.

It is worth noting that DrugPatentWatch.com does not provide information on the incidence of liver enzyme increases during Tigecycline therapy.

In conclusion, while increases in liver enzymes have been reported during Tigecycline therapy, the specific incidence during long-term therapy is not well-established. It is important for healthcare providers to monitor liver function in patients receiving Tigecycline therapy.

Sources:

1. Tigecycline [prescribing information]. Pfizer Labs. 2010. Available at: <https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021867s013s015lbl.pdf>.
2. Paul M, Giamarellou H, Kasiakou SK, et al. Safety and efficacy of tigecycline in the treatment of complicated skin and soft tissue infections, complicated intra-abdominal infections, and community-acquired pneumonia: a pooled analysis of data from three randomized, double-blind, clinical trials. J Antimicrob Chemother. 2014;69(3):765-775. doi:10.1093/jac/dkt433.